AD3 Additive Drug Delivering Devices, L.L.C.

2012 Semi-Finalist

2012 Graduate of the I-CORPS Business Development Course

CTO & co-founder: Dr. Cody Reynolds Email: codyr@AD3llc.com Phone: 971-221-9587 Technical Board of Advisors & co-founders: Dr. Scott Sullivan, Director of Fetal Health at MUSC Dr. Douglas Hirt, Director of Clemsons Dept. of Chemical Engineering Dr. Chris Cox, Professor of Mathematical Sciences at Clemson University

A Growing Need to Prevent Hospital Infections

Surgical site infections occur in 4-14% of all surgeries, costing the US an average $14k per infection or $4.5B-$5.7B annually.
Physicians Hospital Administration
Physicians want to use better versions of the products they are familiar with Mandated to minimize hospital-born infections to reduce costs.

Medical Device Companies

Looking for new attributes to make existing products stand out

Antimicrobial Fibers to Prevent Infections

Strong Value Proposition for Partners and Investors:
Leverages original product brand equity Prolongs brand commercial life Streamlines product development and manufacturing by leveraging original product data Potential for improved product economics

Product Attributes:
Enables 510(k) certification by FDA Extends antimicrobial delivery from 2 weeks to 3 months Can improve established handling qualities

+
Antimicrobials

+ 3 months Triclosan

Altered image of BioMesh for demonstration purposes only, AD3 has no affiliation with Cousin Biotech.

Market Opportunities & Sizes

Our customers are large medical device companies who are actively seeking to invest in and acquire technologies that enhance and prolong their products lives

US Market $1.3B

Synthetic Meshes $1.0B

Anti-infectives $500M Antiinfective Sutures $250M

World-Wide Surgical Mesh Market 2009 $2.3B

World-Wide Suture & Anti-Infective Wound Care 2010 $2.1B

Attracting Corporate Customers

End User Discovery

Interviewed over 50 MDs and 35 medical industry associates to ascertain their unmet needs and receptivity to our product profile. Working to attract surgeons who are early adopters to champion the use of this technology. Demonstrate potential benefit to their cause to gain access to: Milestone-based funding Market awareness via their sponsored programs list

Special Interest Groups

Presenting justification of the viability of the opportunity: Differentiates product offerings from competitors Corporate Increased efficacy justifies much larger margins Partner/Cust $1B US market with a 12.4% CAGR omer IP license or acquisition by the corporate partner

Long-Term Sustainability
Business Model: To demonstrate in vivo performance in order to raise capital and forward integrate to become an OEM focused on antimicrobial medical devices.
Surgeons and medical device companies are both asking for improvements to existing products Growing medical device market: aging US population and the obesity epidemic Incorporated 11/20/2012 Exclusive license is being pursued from CURF In vitro experiments demonstrate product viability A seasoned interim CEO to guide the early stages of the company Laboratory space at an incubator Funding to conduct further studies

Viability

Status

Company Needs